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Jonathan R Seckl and Karen E Chapman
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1Departments of Clinical Biochemistry and Medicine, Cambridge Institute for Medical Research, Addenbrooke’s Hospital, Cambridge CB2 2XY, UK
(Requests for offprints should be addressed to K E Chapman; Email: karen.chapman@ed.ac.uk)AbstractProopiomelanocortin (POMC)deficiency causes severe obesity
through hyperphagia of hypothalamic origin. However, low
glucocorticoid levels caused by adrenal insufficiency mitigate
against insulin resistance, hyperphagia and fat accretion in
PomcK/K mice. Upon exogenous glucocorticoid replacement,
corticosterone-supplemented (CORT) PomcK/K mice show
exaggerated responses, including excessive fat accumulation,
hyperleptinaemia and insulin resistance. To investigate the
peripheral mechanisms underlying this glucocorticoid hyper-
sensitivity, we examined the expression levels of key
determinants and targets of glucocorticoid action in adipose
tissue and liver. Despite lower basal expression of 11b-
hydroxysteroid dehydrogenase type 1 (11b-HSD1), which
generates active glucocorticoids within cells, CORT-mediated
induction of 11b-HSD1 mRNA levels was more pronouncedThis is an Open Access article distributed under the terms of the Society for Endo
distribution, and reproduction in any medium, provided the original work is prop
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0022–0795/07/0194–161 q 2007 Society for Endocrinology Printed in Greatin adipose tissues ofPomcK/Kmice. Similarly, CORT treatment
increased lipoprotein lipase mRNA levels in all fat depots in
PomcK/K mice, consistent with exaggerated fat accumulation.
Glucocorticoid receptor (GR) mRNA levels were selectively
elevated in liver and retroperitoneal fat of PomcK/K mice but
were corrected by CORT in the latter depot. In liver, CORT
increased phosphoenolpyruvate carboxykinase mRNA levels
specifically in PomcK/K mice, consistent with their insulin-
resistant phenotype. Furthermore, CORT induced hyperten-
sion in PomcK/Kmice, independently of adipose or liver renin–
angiotensin system activation. These data suggest that CORT-
inducible 11b-HSD1expression in fat contributes to the adverse
cardiometabolic effects of CORT in POMC deficiency,
whereas higher GR levels may be more important in liver.
Journal of Endocrinology (2007) 194, 161–170Introduction
Glucocorticoids exert pleiotrophic effects on metabolism and
energy partitioning. Centrally, they increase food intake and
reduce energy expenditure, whilst peripherally, they promote
insulin resistance, fat accumulation (Dallman et al. 1993,
Kellendonk et al. 2002) and hypertension (Saruta 1996,
Whitworth et al. 2001). Polymorphisms in the human
glucocorticoid receptor NR3c1 gene (GR) are associated
with glucocorticoid hypersensitivity, visceral obesity, hyper-
tension and increased cardiovascular disease risk (Buemann
et al. 1997, Rosmond et al. 2000, Dobson et al. 2001, Ukkola
et al. 2001a,b, van Rossum et al. 2003). Many rodent models
of obesity are characterised by hypercorticosteronaemia, with
weight gain normalised following adrenalectomy and
reinstated by glucocorticoid replacement (Debons
et al.1982, Freedman et al. 1986, Sainsbury et al.1997,
Makimura et al. 2000). Although plasma glucocorticoid levels
are normal in human idiopathic obesity (Flier 2004), it hasbeen proposed that intra-adipose glucocorticoid action is
selectively increased, through increased adipose expression of
11b-hydroxysteroid dehydrogenase type 1 (11b-HSD1), the
intracellular enzyme that regenerates active glucocorticoids
from intrinsically inert 11-keto-glucocorticoids (Kotelevtsev
et al. 1997, Jamieson et al. 2000, Andrew et al. 2002).
Obese humans (Rask et al. 2001, Paulmyer-Lacroix et al.
2002, Lindsay et al. 2003, Kannisto et al. 2004) and some
rodent models of obesity (Livingstone et al. 2000, Masuzaki
et al. 2001) have selectively increased adipose levels of 11b-
HSD1 and transgenic overexpression of 11b-HSD1 in
adipocytes causes hyperphagia, obesity, insulin resistance
and hypertension despite unchanged systemic glucocorticoid
levels (Masuzaki et al. 2001, 2003). Hepatic overexpression of
11b-HSD1 has no effect on adiposity, but causes hypertension
and insulin resistance (Paterson et al. 2004). Conversely, mice
deficient in 11b-HSD1 are insulin sensitised and resist the
adverse metabolic effects of a high-fat diet (Kotelevtsev et al.
1997, Morton et al. 2001, 2004).crinology’s Re-use Licence which permits unrestricted non-commercial use,
erly cited.
DOI: 10.1677/JOE-07-0090
Britain Online version via http://www.endocrinology-journals.org
Z MICHAILIDOU and others . Glucocorticoid action in Pomc null mice162Proopiomelanocortin (POMC) is a polypeptide precursor
which undergoes extensive post-translational modification to
yield a range of smaller, biological active peptides.These include
a-, b- and g-melanocyte-stimulating hormone and adreno-
corticotrophic hormone (ACTH), collectively known as
melanocortins. Inactivating mutations of the POMC gene in
humans and mice result in a complex phenotype. Loss of
melanocortin signalling within the hypothalamus causes
hyperphagia and obesity (Krude et al. 1998, Yaswen
et al.1999, Challis et al. 2004). Further, a failure to produce
ACTHwithin the anterior pituitary causes adrenal insufficiency
with low or absent circulating glucocorticoids (Krude et al.
1998, Yaswen et al.1999, Challis et al. 2004). PomcK/Kmice are
therefore unusual amongst rodent models in that obesity
develops in the absenceof circulatingglucocorticoids.However,
glucocorticoid treatment exacerbates hyperphagia and obesity
in adult PomcK/K mice and induces severe insulin resistance,
hyperleptinaemia and diabetes (Coll et al. 2005).
We have tested the hypothesis that increased glucocorticoid
action in peripheral tissues of glucocorticoid-treated PomcK/K
mice contributes to their apparent glucocorticoid hypersensi-
tivity and exaggeratedmetabolic syndrome-like phenotype.We
further demonstrate that glucocorticoid replacement induces
hypertension in PomcK/K mice, independently of renin–
angiotensin system (RAS) activation.Materials and Methods
Animals and CORT replacement
ThegenerationofPomcK/Kmiceon a129/SvEvbackgroundhas
been described previously (Challis et al. 2004). All mice were
housed in standard conditions on a 12 h light:12 h darkness cycle
(lights on 0070 h) with ad libitum access towater and chow (4.5%
fat diet, Special Diet Services, Witham, UK). Eight-week-old
male mice (nZ5 per group) were treated with corticosterone
(25 mg/ml) in their drinking water, a dose that results in similar
plasma glucocorticoid levels and hypothalamic corticotrophin
releasing hormone (CRH)mRNA levels in PomcK/K and wild-
type mice (Coll et al. 2005). All animal protocols used in these
studieswere approvedunder the auspices of theUKHomeOffice
Animals (Scientific Procedures) Act 1986.Blood pressure measurement
Systolic bloodpressurewasmeasured photoelectrically in the tail
of restrained conscious mice using an IITC model 179 analyser
(WoodlandHills, CA, USA). Prior to recordingmeasurements,Figure 1 Mediators of GC action in adipose tissue of PomcK/Kmice an
northern blot showing levels of 11b-HSD1 mRNA and 18S RNA in ep
mice, either untreated or treated for 10 days with corticosterone (cort). (
LPL (D) and PEPCK (E) mRNA levels in experimental mice. Epi, epidid
presented as percentage of the value in untreated wild-type mice (100
0.05, **P!0.01 and ***P!0.001.
Journal of Endocrinology (2007) 194, 161–170all mice underwent three periods of training to accustom them
to the procedure.Micewerewarmed at 32 8C for 30 min before
taking ten consecutive readings. The first five were discounted
and a mean value of systolic blood pressure was calculated from
the last five readings. Fivemice from each treatment groupwere
measured. All analogue recordings were analysed by an
independent observer who was blinded to the genotype of the
mice and any treatment they had received.Plasma hormone and lipid measurements
Animals were killed between 0800 and 0900 h by cervical
dislocation. Trunk blood samples were collected into EDTA-
coated tubes (Sarstedt, Leicester, UK), centrifuged at 6000 g for
10 min and plasma stored at K80 8C until required for assay.
Non-esterified fatty acid (NEFA) and triglyceride levels were
determined by commercial kits (NEFA, Roche Diagnostics;
triglyceride, Dade Behring, Marburg, Germany). Plasma renin
and angiotensinogen concentrations were determined as
previously described (Morton et al. 2005).Tissue morphology and hepatic triglyceride levels
Neutral lipids, cholesterol and fatty acidswere identified by light
microscopy at 40! magnification in cryostat liver sections
(30 mm) stainedwith oil redO (Sigma) and counter stainedwith
haematoxylin as previously described (Morton et al. 2005).
Hepatic triglycerides were extracted by homogenisation in
isopropanol (ten volumes) and then incubated at 37 8C for
45 min and measured spectrophotometrically in supernatants
(3000 g for 10 min) using reagent TR224221 (Alpha Labora-
tories, Eastleigh, Hampshire, UK).RNA extraction and northern blot analysis
Pieces of liver and adipose tissues (inguinal, retroperitoneal and
epididymal) were rapidly frozen in dry ice, stored atK80 8C and
then homogenised inTrizol reagent (Invitrogen). TotalRNAwas
purified using a binding matrix (RNaid Plus kit, BIO 101;
Anachem,UK) and eluted in diethylpyrocarbonate-treatedwater
containing 400 U/ml RNasin (Promega) and 10 mmol/l
dithiothreitol. RNA (5–10 mg) was blotted and hybridised to
32P-labelled cDNA probes for mouse 11b-HSD1, GR,
angiotensinogen, phosphoenolpyruvate carboxykinase
(PEPCK), lipoprotein lipase (LPL) and 18S as previously
described (Morton et al. 2005). SpecificmRNAswere quantified
using a phosphorimager (Fuji BAS FLA 2000, Raytek, Sheffield,d effects of CORT treatment on GC target genes. (A) Representative
ididymal adipose tissue of PomcK/K (K/K) and wild-type (C/C)
B–E) Quantitation of adipose tissue-specific 11b-HSD1 (B), GR (C),
ymal fat; ing, inguinal fat; retro, retroperitoneal fat. Data are
%) and are the meansGS.E.M.; nZ5 per group. Significance *P!
www.endocrinology-journals.org
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in arbitrary units relative to 18S RNA.Statistical analyses
The effects of genotype and corticosterone interactions were
assessed by two-way ANOVA followed by post hoc Tukey’s
tests for group differences. Significance was set at P!0.05.
Values are meansGS.E.M.Results
PomcK/K mice have reduced intra-adipose GC action but
exaggerated CORT-mediated GC amplification
Corticosterone-treated PomcK/K and wild-type mice had
similar plasma corticosterone levels and hypothalamic CRH
mRNA levels (Coll et al. 2005). To examine potential
mechanisms of corticosterone hypersensitivity in PomcK/K
mice, 11b-HSD1 and GR mRNA levels were measured in
epididymal, inguinal and retroperitoneal adipose depots.
Adipose 11b-HSD1 mRNA expression was lower in all
untreated PomcK/K compared with wild-type mice (Fig. 1A)
and was dramatically increased by corticosterone in both
genotypes (Fig. 1A), with larger increases (two- to four-fold
greater) in PomcK/K mice.
Adipose expression of GR mRNA was higher in the
retroperitoneal fat of PomcK/K mice and restored to wild-
type levels by corticosterone treatment (Fig. 1B). GR mRNA
levels did not differ in inguinal and epididymal fat between
PomcK/K and wild-type mice, and were unaffected by
corticosterone treatment in either genotype (Fig. 1B).
To investigate mechanisms downstream of 11b-HSD1/GR
by which corticosterone treatment selectively increases fat mass
in PomcK/K mice, adipose levels of mRNA encoding LPL, a
glucocorticoid-regulated gene (Fried et al. 1993), were
measured. Although LPL mRNA levels were the same in
untreated PomcK/K and wild-type mice in all depots, adipose
LPL expression in PomcK/K mice was markedly increased by
corticosterone treatment (Fig. 1C) consistent with increased
triglyceride uptake, and fatmass inPomcK/Kmice. Inwild-type
mice, corticosterone treatment increased LPL mRNA only in
the inguinal depot, and to a lesser extent than in PomcK/Kmice
(Fig. 1C), suggesting adipose depot-dependent regulation of
LPL by glucocorticoids in non-obese mice, consistent with
previous data in rats (Freedman et al. 1986).
PEPCK is an enzyme essential for gluconeogenesis in liver
and glycerol synthesis in adipose tissue (Pilkis & Granner
1992, Reshef et al. 2003). PEPCK is a classical glucocorticoid
target gene which is positively regulated by glucocorticoids in
hepatocytes and negatively regulated in adipocytes (Sasaki
et al.1984, Nechushtan et al. 1987). Consistent with this,
adipose PEPCK mRNA levels were decreased in epididymal
and retroperitoneal fat by corticosterone treatment in wild-
type mice (Fig. 1D). Surprisingly, given their glucocorticoidJournal of Endocrinology (2007) 194, 161–170deficiency, PomcK/K mice had lower levels of PEPCK
mRNA in adipose tissue than in wild-type (Fig. 1D).
However, although corticosterone treatment in PomcK/K
mice decreased PEPCK expression in inguinal and retro-
peritoneal adipose tissue (significantly lower than in
corticosterone-treated wild-type mice; PZ0.01), it had no
effect on PEPCK mRNA levels in epididymal adipose tissue,
suggesting that other regulatory factors dominate PEPCK
expression in adipose tissue of PomcK/K mice (Fig. 1D).PomcK/K mice are dyslipidaemic, and have unaltered hepatic
11b-HSD1 but higher GR mRNA levels
Hepatic 11b-HSD1 mRNA levels were similar between the
two genotypes (Fig. 2A) and unaffected by corticosterone
(Fig. 2A). Hepatic GRmRNA levels were higher in PomcK/K
compared with wild-type mice (Fig. 2B), but again
corticosterone had no effect on GR mRNA levels (Fig. 2B).
Hepatic PEPCK expression was lower in PomcK/K than in
wild-type mice (Fig. 2C) and was increased by corticosterone
treatment to levels equivalent to untreated wild-type mice. In
contrast, corticosterone decreased hepatic PEPCK mRNA
levels in wild-type mice (Fig. 2C).
PomcK/K mice showed markedly higher circulating trigly-
ceride levels (Fig. 3A) and hepatic lipid accumulation thanwild-
type mice (Fig. 3B), with sixfold higher levels of hepatic
triglyceride (P!0.001; Fig. 3C). However, corticosterone had
no effect on plasma triglyceride levels in either genotype
(Fig. 3A), nor did it worsen the liver phenotype (Fig. 3C).
PomcK/K and wild-type mice had similar plasma NEFA levels
which were unaffected by corticosterone (Fig. 3D).CORT drives hypertension in PomcK/K mice independently of
adipose and liver RAS activation
PomcK/K mice had similar blood pressure to wild-type mice
(Fig. 4A). Corticosterone markedly increased blood pressure
only inPomcK/Kmice (Fig. 4A). Since hypertension following
transgenic expression of 11b-HSD1 in adipose or liver is
associated with increased levels of angiotensinogen in each of
these tissues respectively (Masuzaki et al. 2001, Paterson et al.
2004), we hypothesised that a similar mechanism may drive
corticosterone-mediated hypertension in PomcK/K mice. We
therefore examined key components of the RAS (Guyton
1991). PomcK/K mice had higher hepatic angiotensinogen
mRNA levels than controls (Fig. 4B). However, corticoster-
one did not alter hepatic angiotensinogen mRNA levels in
either genotype (Fig. 4B). Consistent with lower intra-adipose
GC action, adipose angiotensinogenmRNA levels were lower
in PomcK/K mice in all adipose depots (Fig. 4C). Corticos-
terone increased angiotensinogen mRNA levels specifically in
epididymal adipose tissue of both genotypes (twofold increase;
P!0.001; Fig. 4C) but had no effect on angiotensinogen
mRNA levels in inguinal or retroperitoneal adipose tissue of
either genotype (Fig. 4C). Plasma angiotensinogenwww.endocrinology-journals.org
Figure 2 Mediators of GC action in the liver of PomcK/K mice and
effects of CORT treatment on GC target genes. Liver mRNA
expression of (A) 11b-HSD1, (B) GR and (C) PEPCK in PomcK/K
(K/K) and wild-type (C/C) mice, either untreated or treated for
10 days with corticosterone (cort). Data are presented as
percentages of the value in untreated control mice (100%) and are
the meansGS.E.M.; nZ5 per group. Significance *P!0.05, **P!
0.01 and ***P!0.001.
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www.endocrinology-journals.orgconcentrations did not differ with genotype or corticosterone
(Fig. 4D). As has been found in another model of
glucocorticoid-deficient obesity (Morton et al. 2005), plasma
renin concentration was markedly higher in PomcK/K mice
(Fig. 4E) but this was unaffected by corticosterone (Fig. 4E).Discussion
Increased glucocorticoid action specifically in adipose
(Masuzaki et al. 2001) or liver (Paterson et al. 2004) produces
distinct metabolic syndromes with hypertension. Increased
GR sensitivity is also associated with altered fat distribution,
hypertension and cardiometabolic disease (Buemann et al.
1997, Rosmond et al. 2000, Dobson et al. 2001, Ukkola et al.
2001a,b, van Rossum et al. 2003). We hypothesised that
altered tissue regeneration of active glucocorticoid and/or
peripheral tissue sensitivity to GCs might explain in part the
exaggerated fat accumulation, insulin resistance (Coll et al.
2005) and the hypertension observed in PomcK/K mice with
glucocorticoid replacement.
With fixed circulating glucocorticoid levels, 11b-HSD1
and GR expression levels are the key determinants of GC
action. PomcK/K mice had lower adipose but similar hepatic
levels of 11b-HSD1 mRNA levels to wild-type mice.
Corticosterone treatment dramatically and more markedly
increased 11b-HSD1 in the adipose tissue of PomcK/K mice.
This was accompanied by a marked increase in the expression
of the glucocorticoid-inducible (Fried et al. 1993) gene LPL,
which is consistent with the exaggerated accumulation of fat
in these mice. Intriguingly, these data suggest that, at least in
adipose tissue, 11b-HSD1 itself is a glucocorticoid target
gene. This finding is consistent with most (Hammami &
Siteri 1991, Jamieson et al. 1995, Voice et al. 1996, Bujalska
et al. 1999), but not all (Napolitano et al. 1998) previous
reports of glucocorticoid induction of 11b-HSD1 in a variety
of cell types. Although not specifically measured here,
increased adipose 11b-HSD1 activity is predicted to
selectively amplify intra-adipose glucocorticoid concen-
trations, particularly when circulating levels of substrate are
high. On the other hand, our data suggest that congenital
glucocorticoid deficiency has little impact upon hepatic 11b-
HSD1 levels in vivo and is not regulated by corticosterone. In
contrast, 11b-HSD1 mRNA levels are highly and positively
regulated by glucocorticoids in adipose tissue.
GR levels are another major determinant of cellular
glucocorticoid sensitivity (Vanderbilt et al. 1987, Geley et al.
1996). Small differences in GR mRNA levels can markedly
alter glucocorticoid responsiveness (Geley et al. 1996,
Reichardt et al. 2000). PomcK/K mice had elevated GR
mRNA levels in liver and retroperitoneal adipose tissue,
suggesting increased glucocorticoid sensitivity selectively in
these depots. Following corticosterone replacement in
PomcK/K mice, GR mRNA levels were restored to wild-
type levels in retroperitoneal adipose tissue but not in liver,
consistent with tissue- and time-specific differences in GRJournal of Endocrinology (2007) 194, 161–170
Figure 3 Dyslipidaemia and fatty liver in PomcK/K mice. (A) Plasma triglyceride levels in PomcK/K (K/K)
and wild-type (C/C) mice, either untreated or treated for 10 days with corticosterone (cort). (B) Oil Red O
staining of neutral lipid in liver sections of wild-type mice (C/C, left upper panel), CORT-treated wild-type
mice (C/C, left bottom panel), PomcK/K (K/K, right upper panel) and CORT-treated PomcK/K (K/K, right
bottom panel). Magnification is 40!; red, oil red O; blue, haematoxylin (nuclei). (C) Hepatic triglyceride
content in PomcK/K (K/K) and wild-type (C/C) mice, either untreated or treated for 10 days with
corticosterone (cort). (D) Plasma levels of non-esterified fatty acids (NEFA) in PomcK/K (K/K) and wild-type
(C/C) mice, either untreated or treated for 10 days with corticosterone (cort). Data are meansGS.E.M.; (nZ6
per group). Significance ***P!0.001.
Z MICHAILIDOU and others . Glucocorticoid action in Pomc null mice166autoregulation (Kalinyak et al. 1987, Dong et al. 1988,
Sheppard et al. 1990, Holmes et al., 1995, 1997, Reichardt
et al. 2000).
Corticosterone had no additional effects on the hyper-
triglyceridaemia and fatty liver of the PomcK/K mice, and did
not affect plasma NEFAs, which were normal in PomcK/K
mice. The corticosterone-driven caloric excess in PomcK/K
mice may drive a further increase in the flux of triglycerides
from the liver, that, coupled with increased adipose uptake via
LPL, maintains the circulating and liver triglyceride levels
constant and is consistent with increased adipose tissue mass in
corticosterone-treated PomcK/K mice (Coll et al. 2005).
Adipose PEPCK is critical for glyceroneogenesis and is thus
a key regulator of the level of fatty acid re-esterification
(reviewed in Reshef et al. 2003). Unexpectedly, since
glucocorticoids reduce adipose PEPCK, glucocorticoid-Journal of Endocrinology (2007) 194, 161–170deficient PomcK/K mice had lower levels of PEPCK
mRNA in all adipose depots. This was further decreased by
corticosterone treatment. The lower level of PEPCK mRNA
in untreated PomcK/K mice may be due to their higher fed
blood glucose levels (Nechushtan et al. 1987, Opherk et al.
2004), thus reducing the need for glyceroneogenesis to
generate glycerol phosphate for fatty acid re-esterification.
PomcK/K mice have lower hepatic expression of PEPCK.
This may not be due to the lack of glucocorticoid signalling in
liver, as mice with a liver-specific knockout of GR have
normal levels of PEPCK in liver (Opherk et al. 2004), but may
be related to the higher circulating levels of insulin in
PomcK/K mice compared with wild-type (Coll et al. 2005).
Insulin dominantly and negatively suppresses hepatic PEPCK
in the fed state (Pilkis & Granner 1992). In corticosterone-
treated wild-type mice, the repressive effect of insulinwww.endocrinology-journals.org
Figure 4 Corticosterone treatment increases blood pressure in PomcK/K mice: effect of CORT treatment on
the Renin-angiotensin system. Effect of 10 days corticosterone treatment (cort) on (A) systolic blood pressure,
(B) renin concentration, (C) plasma angiotensinogen, (D) angiotensinogen (Agt) mRNA in adipose tissue (AT),
and (E) angiotensinogen (Agt) mRNA levels in liver in wild-type (C/C) and PomcK/K (K/K) mice. Epi,
epididymal fat; ing, inguinal fat; retro, retroperitoneal fat. Data are meansGS.E.M., and for transcript levels
are expressed relative to levels in untreated wild-type mice (100%); nZ5 per group. Significance *P!0.05,
**P!0.01 and ***P!0.001.
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these mice compared with untreated wild-type mice may
reflect the increase in insulin levels following corticosterone
(Coll et al. 2005). In contrast, hepatic PEPCK mRNA levels
doubled following corticosterone treatment in PomcK/K
mice, consistent with hepatic insulin resistance and marked
hyperinsulinaemia (Coll et al. 2005).
Blood pressure in PomcK/K mice is normal despite their
hypoadrenal state. This implies that secondary mechanisms
are invoked to maintain cardiovascular function when
circulating aldosterone and corticosterone concentrations
are chronically reduced (Coll et al. 2004). It seems likely
that the increased renin activity which we have observed in
PomcK/K mice is part of this adaptive process. However,
corticosterone replacement did not normalise renin activity
and selectively increased blood pressure in PomcK/K mice.
This was not attributed to a further activation of the
circulating RAS, since neither renin nor its substrate
angiotensinogen was increased. Indeed, the expression of
angiotensinogen mRNA in liver and adipose tissues did not
correlate with blood pressure. It seems likely that corticos-
terone augmented existing mechanisms that were already
sustaining vascular function. Apart from renin, these
secondary processes are likely to involve the hyper-
insulinaemic (Sowers 2004) state of PomcK/K mice (which
is exacerbated by corticosterone treatment; Coll et al. 2005),
the sympathetic nervous system (Rascher et al. 1979; which is
thought to explain glucocorticoid-induced hypertension in
normal mice) or structural adaptation of the vasculature
(Wallerath et al. 2004).
In summary, we show that increased adipose tissue-specific
sensitivity to glucocorticoids in PomcK/K mice may result in
part from exaggerated induction of 11b-HSD1 in adipose
tissue with corticosterone administration. Whilst acknowl-
edging that mRNA changes do not always translate to altered
protein (or enzyme activity) levels, these data nevertheless
suggest that 11b-HSD1 might be a more potent mediator of
intra-adipose GC action than the GR levels, whereas in liver,
higher GR levels contribute to the diabetogenic phenotype of
the PomcK/K mice.Acknowledgements
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